- Navin Molecular inaugurated Phase-1 of its new cGMP-4 facility at the NFIL Dewas unit on 4 September 2025.
- The inauguration was attended by company leadership and its European partner.
Navin Molecular has inaugurated Phase-1 of its new cGMP-4 facility at the NFIL Dewas unit, marking a step in its expansion of specialty chemicals and CDMO services. The ceremony took place on 4 September 2025 in the presence of the company’s European partner.
The event was attended by Chairman Mr. Vishad P. Mafatlal, Managing Director Mr. Nitin Kulkarni, and the leadership team of Navin Fluorine International Ltd. The new facility has been described as state-of-the-art, designed to support global partners with advanced technologies and high standards.
The cGMP-4 site is expected to strengthen the company’s ability to deliver contract manufacturing solutions, while maintaining an emphasis on quality and value. According to the release, the investment reflects a continuing commitment to innovation and reliability.
“The inauguration of this state-of-the-art facility marks another significant step in our commitment to innovation, reliability, and world-class standards in specialty chemicals and CDMO services,” the company stated.
